Medical Marijuana Giant Aurora Will Soon Report Earnings, Here's What Investors Need To Know
Medical Marijuana Giant Aurora Will Soon Report Earnings, Here's What Investors Need To Know
Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) has scheduled a conference call to discuss the results for its first quarter 2025 on Wednesday, August 7, 2024 at 8:00 am ET.
Aurora Cannabis Inc.（纳斯达克：ACB）（tsx：ACB）已安排一次电话会议，讨论2025年第一季度的业绩，将于2024年8月7日星期三上午8:00 ET。
The Canadian medical marijuana giant will report its financial results for the first quarter of 2025 before the opening of markets that same day. CEO Miguel Martin and CFO Simona King will host the conference call and question and answer period.
这家加拿大医用大麻巨头将在当天市场开盘之前公布其2025年第一季度的财务业绩。首席执行官Miguel Martin和首席财务官Simona King将主持电话会议和问答环节。
Aurora made headlines last week as it was granted two licenses by the Federal Institute for Drugs and Medical Devices (BfArM) under Germany's new Medical Cannabis Act (MedCanG). The permits granted the company continued domestic cultivation, which has been underway for two years.
上周，极光大麻因在德国新的医疗大麻法案（MedCanG）下获得德国联邦药品和医疗器械研究所（BfArM）的两个许可证而成为新闻头条。这些许可证授予公司继续国内种植的权利，这项工作已进行了两年。
Pablo Zuanic, a seasoned marijuana stock analyst from Zuanic & Associates, recently highlighted the company's need to prove its growth strategies amid an increasingly competitive and uncertain global landscape.
来自Zuanic & Associates的经验丰富的大麻股票分析师Pablo Zuanic最近强调了该公司在日益竞争和不确定的全球环境中证明其增长策略的需求。
"ACB is among the two largest medical cannabis companies globally and stands to benefit significantly from nascent international markets, which we estimate could see a tenfold increase over the next decade," Zuanic wrote.
"ACB是全球两大医用大麻公司之一，将受益于新兴国际市场，我们估计未来十年其中市场规模可能增长十倍，" Zuanic写道。
Read Also: Another Cannabis Pioneer Expands In Germany Via Acquisition As Experts Say 'There's No Stepping Back' From Legalization Wave
阅读也可以看到：另一家大麻先驱公司通过收购在德国扩大，而专家表示‘无法从合法化潮流中后退'
Aurora targets a long-term market share of 10% in the international medical marijuana market, potentially increasing its international medical marijuana sales to roughly CA$700 million ($505.8 million). Current annualized international proforma revenues are CA$100 million.
极光大麻的目标是在国际医用大麻市场上获得10%的长期市场份额，可能将其国际医用大麻销售额提高到大约CA$70000万（$50580万）。当前国际预估收入的年化水平为CA$10000万。
In its latest earnings report, the company said its global medical cannabis net revenue grew by 20% year-over-year to CA$45.6 million in the fourth quarter of fiscal 2023. The increase in net revenue1 of $7.7 million was primarily due to higher sales to Australia and Europe in the current period following the success of newly launched innovative cultivars in these markets.
在其最新的财报中，该公司表示，其全球医用大麻净营业收入同比增长20％，到2023财年第四季度的CA$4560万。$770万净营收增长主要是由于在这些市场新推出创新品种后，在当前期间向澳大利亚和欧洲的销售增加。
- Aurora Cannabis Launches 1.2g Resin Cartridges In Australia, Now Available For Doctors To Prescribe
- 极光大麻推出1.2克树脂笔芯在澳大利亚，现在可以为医生开处方。
To learn more about cannabis stocks and investing, come join us at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.
未经公允价值调整的综合调整毛利率为49％，去年同期为CA31.6百万。